Inflammation of the mucosal layer of the gastrointestinal (GI) tract is not only a feature almost always associated with ulceration of those tissues, but it also plays an important role in both the production and healing of the lesions. The mediators that coordinate inflammatory responses also have the capability to alter the resistance of the mucosa to injury induced by noxious substances, while others render the mucosa more susceptible to injury. In this article, we provide a review of the inflammatory mediators that modulate GI mucosal defense. Among the mediators discussed are nitric oxide, the eicosanoids (prostaglandins, leukotrienes, and thromboxanes), neuropeptides, cytokines, and proteinases. Many of these mediators are considered potential therapeutic targets for the treatment of ulcerative diseases of the digestive tract.
WallaceJL, GrangerDN. The cellular and molecular basis of gastric mucosal defence. FASEB J10:731–740, 1996.
2.
SandersMJ, AyalonA, RollM, SollAH. The apical surface of canine chief cell monolayers resists H+ back-diffusion. Nature313:51–54, 1985.
3.
PaimelaH, GoddardPJ, SilenW.Present views on restitution of gastrointestinal epithelium. Dig Dis Sci40:2495–2496, 1995.
4.
HolzerP, LivingstonEH, SariaA, GuthPH. Sensory neurons mediate protective vasodilatation in rat gastric mucosa. Am J Physiol260:G363–G370, 1991.
5.
BeckPL, McKnightW, LeeSS, WallaceJL. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. Am J Physiol265:G453–G458, 1993.
6.
FerrazJGP, McKnightW, SharkeyKA, WallaceJL. Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. Gastroenterology108:1183–1191, 1995.
7.
WallaceJL. Mechanisms of protection and healing: current knowledge and future research. Am J Med110(Suppl 1):S19–S23, 2001.
8.
WallaceJL, MillerMJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology119:512–520, 2000.
9.
MillerMJ, SandovalM.Nitric oxide: III. A molecular prelude to intestinal inflammation. Am J Physiol276:G795–G799, 1999.
10.
WhittleBJR, Lopez-BelmonteJ, MoncadaS.Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol99:607–611, 1990.
11.
MacNaughtonWK, CirinoG, WallaceJL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci45:1869–1876, 1989.
12.
WallaceJL, ReuterB, CicalaC, McKnightW, GrishamMB, CirinoG.Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology107:173–179, 1994.
ReuterBK, CirinoG, WallaceJL. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci55:PL1–PL8, 1994.
15.
ElliottSN, McKnightW, CirinoG, WallaceJL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology109:524–530, 1995.
16.
KubesP, McCaffertyD-M. Nitric oxide and intestinal inflammation. Am J Med109:150–158, 2000.
17.
KanwarS, WallaceJL, BefusD, KubesP.Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. Am J Physiol266:G222–G229, 1994.
18.
KubesP.Nitric oxide modulates epithelial permeability in the feline small intestine. Am J Physiol262:G1138–G1142, 1992.
19.
HogaboamCM, BefusAD, WallaceJL. Modulation of rat mast cell reactivity by IL-1β: divergent effects on nitric oxide and platelet-activating factor release. J Immunol151:3767–3774, 1993.
20.
SalveminiD, MasiniE, PistelliA, MannaioniPF, VaneJR. Nitric oxide: a regulatory mediator of mast cell reactivity. J Cardiovasc Pharmacol17:S258–S264, 1991.
21.
RachmilewitzD, StamlerJS, KarmeliF, MullinsME, SingelDJ, LoscalzoJ, XavierRJ, PodolskyDK. Peroxynitrite-induced rat colitis: a new model of colonic inflammation. Gastroenterology105:1681–1688, 1993.
22.
MillerMJS, ThompsonJH, ZhangXJ, Sadowska-KrowickaH, KakkisJL, MunshiUK, SandovalM, RossiJL, Eloby-ChildressS, BeckmanJS, YeYZ, RodiCP, ManningPT, CurrieMG, ClarkDA. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology109:1475–1483, 1995.
23.
HogaboamCM, JacobsonK, CollinsSM, BlennerhassettMG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol268:G673–G684, 1995.
24.
RachmilewitzD, KarmeliF, OkonE, BursztynM.Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut37:247–255, 1995.
25.
KubesP, ReinhardtPH, PayneD, WoodmanRC. Excess nitric oxide does not cause cellular, vascular, or mucosal dysfunction in the cat small intestine. Am J Physiol269:G34–G41, 1995.
26.
WallaceJL, VergnolleN, MuscaraMN, AsfahaS, ChapmanK, McKnightW, Del SoldatoP, MorelliA, FiorucciS.Enhanced antiinflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology117:557–566, 1999
27.
RobertA.Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prost Thrombox Res2:507–520, 1976.
28.
VaneJR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol231:232–235, 1971.
29.
WallaceJL. Gastric ulceration: critical events at the neutrophil-endothelium interface. Can J Physiol Pharmacol71:98–102, 1993.
WallaceJL, KeenanCM, GaleD, ShoupeTS. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology101:18–27, 1992.
32.
HawkeyCJ, RamptonDS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment?Gastroenterology89:1162–1188, 1985.
33.
AsakoH, KubesP, WallaceJL, GaginellaT, WolfRE, GrangerDN. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol262:G903–G908, 1992.
34.
AsakoH, KubesP, WallaceJL, WolfRE, GrangerDN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology103:146–152, 1992.
35.
WoolvertonCJ, WhiteJJ, SartorRB. Eicosanoid regulation of acute intestinal vascular permeability induced by intravenous peptidoglycan polysaccharide polymers. Agents Actions26:301–309, 1989.
36.
KunkelSL, WigginsRC, ChensueSW, LarrickJ.Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun137:404–410, 1986.
SantucciL, FiorucciS, GiansantiM, BrunoriPM, DiMatteoFN, MorelliA.Pentoxifylline prevents indomethacin-induced acute mucosal damage in rats: role of tumour necrosis factor-α. Gut35:909–915, 1994.
39.
SpataforaM, ChiapparaG, D'AmicoD, VolpesD, MelisM, PaceE, MerendinoA.Effect of indomethacin on the kinetics of tumour necrosis factor-α release and tumour necrosis factor-α gene expression by human blood monocyte. Pharmacol Res23:247–257, 1991.
40.
MartichGD, DannenRL, CeskaM, SaffrediniAF. Detection of interleukin-8 and tumour necrosis factor in normal humans after intravenous endotoxin administration: the effect of anti-inflammatory agents. J Exp Med173:1021–1024, 1991.
KunkelSL, ChensueSW, PhanSH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol136:186–192, 1986.
43.
HamEA, SodermanDD, ZanettiME, DoughertyHW, McCauleyE, KuehlFA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A80:4349–4353, 1983.
44.
HaurandM, FlohL.Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate: physiological triggers and modulation by prostanoids. Biochem Pharmacol38:2129–2137, 1989.
45.
WertheimWA, KunkelSL, StandifordTJ, BurdickMD, BeckerFS, WilkeCA, GilbertAR, StrieterRM. Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. J Immunol151:2166–2175, 1993.
46.
RaudJ.Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell-dependent inflammation. Br J Pharmacol99:449–454, 1990.
47.
HogaboamCM, BissonnetteEY, ChinBC, BefusAD, WallaceJL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology104:122–129, 1993.
48.
HernandezLA, GrishamMB, TwohigB, ArforsKE, HarlanJM, GrangerDN. Granulocytes: the culprit in ischemic damage to the intestine. Am J Physiol253:H699–H703, 1987.
49.
WallaceJL, GrangerDN. Pathogenesis of NSAID gastropathy: are neutrophils the culprits?Trends Pharmacol Sci13:129–131, 1992.
50.
GrishamMB, GrangerDN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci33:6S–15S, 1988.
51.
WallaceJL, HigaA, McKnightGW, MacIntyreDE. Prevention and reversal of experimental colitis by a monoclonal antibody which inhibits leukocyte adherence. Inflammation16:343–354, 1992.
52.
WongK, FreundF.Inhibition of n-formylmethiony-leucyl-phenyl-alanine induced respiratory burst in human neutrophils by adrenergic agonists and prostaglandins of the E series. Can J Physiol Pharmacol59:915–920, 1981.
53.
GryglewskiRJ, SzczeklikA, WandzilakM.The effect of six prostaglandins, prostacyclin and iloprost on generation of superoxide anions by human polymorphonuclear leukocytes stimulated by zymosan or formyl-methionyl-leucyl-phenylalanine. Biochem Pharmacol36:4209–4212, 1987.
54.
XieW, ChipmanJG, RobertsonDL, EriksonRL, SimmonsDL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A88:2692–2696, 1991.
55.
XieW, RobertsonDL, SimmonsDL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res25:249–265, 1992.
56.
WallaceJL. Selective COX-2 inhibitors: is the water becoming muddy?Trends Pharmacol Sci1999; 20:4–6.
57.
WallaceJL, BakA, McKnightW, AsfahaS, SharkeyK, MacNaughtonM.Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology115:101–109, 1998.
58.
SmithCJ, ZhangY, KoboldtCM, MuhammadJ, ZweifelBS, ShafferA, TalleyJJ, MasferrerJL, SeibertK, IsaksonPC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A95:13313–13318, 1998.
59.
MorhamSG, LangenbachR, LoftinCD, TianoHF, VouloumanosN, JennetteJC, MahlerJF, KluckmanKD, LedfordA, LeeCA, TestaR, SmithiesO.Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell83:473–482, 1995.
60.
GilroyDW, Colville-NashPR, WillisD, ChiversJ, Paul-ClarkMJ, WilloughbyDA. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med5:698–701, 1999.
61.
KargmanS, CharlesonS, CartwrightM, FrankJ, RiendeauD, ManciniJ, EvansJ, O'NeillG.Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology111:445–454, 1996.
62.
DaviesNM, SharkeyKA, AsfahaS, MacnaughtonWK, WallaceJL. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther11:1101–1108, 1997.
63.
MaricicN, EhrlichK, GretzerB, SchuligoiR, RespondekM, PeskarBM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol128:1659–1666, 1999.
64.
GretzerB, EhrlichK, MaricicN, LambrechtN, RespondekM, PeskarBM. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol123:927–935, 1998.
65.
MizunoH, SakamotoC, MatsudaK, WadaK, UchidaT, NoguchiH, AkamatsuT, KasugaM.Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology112:387–397, 1997.
66.
ReuterBK, AsfahaS, BuretA, SharkeyKA, WallaceJL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest98:2076–2085, 1996.
67.
SilversteinFE, FaichG, GoldsteinJL, SimonLS, PincusT, WheltonA, MakuchR, EisenG, AgrawalNM, StensonWF, BurrAM, ZhaoWW, KentJD, LefkowithJB, VerburgKM, GeisGS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. J Am Med Assoc284:1247–1255, 2000.
68.
BombardierC, LaineL, ReicinA, ShapiroD, Burgos-VargasR, DavisB, DayR, FerrazMB, HawkeyCJ, HochbergMC, KvienTK, SchnitzerTJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med343:1520–1528, 2000.
VaananenPM, KeenanCM, GrishamMB, WallaceJL. A pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy. Inflammation16:227–240, 1992.
71.
YoshidaN, TakemuraT, GrangerDN, AndersonDC, WolfRE, McIntireLV, KvietysPR. Molecular determinants of aspirin-induced neutrophil adherence to endothelial cells. Gastroenterology105:715–724, 1993.
72.
KasirgaE, CokerI, AydogduS, YagciRV, TaneliB, GousseinovA.Increased gastric juice leukotriene B4, C4 and E4 concentrations in children with Helicobacter pylori colonization. Turk J Pediatr41:335–339, 1999.
73.
SharonP, StensonWF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology86:453–460, 1984.
74.
SharonP, StensonWF. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease. Gastroenterology88:55–63, 1985.
75.
ZipserRD, NastCC, LeeM, KaoHW, DukeR.In vivo production of leukotriene B4 and leukotriene C4 in rabbit colitis: relationship to inflammation. Gastroenterology92:33–39, 1987.
76.
WallaceJL, MacNaughtonWK, MorrisGP, BeckPL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology96:29–36, 1989.
77.
WallaceJL, KeenanCM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol258:G527–G534, 1990.
78.
LobosEA, SharonP, StensonWF. Chemotactic activity in inflammatory bowel disease: role of leukotriene B4. Dig Dis Sci32:1380–1388, 1987.
79.
WallaceJL, KeenanCM. Leukotriene B4 potentiates colonic ulceration in the rat. Dig Dis Sci35:622–629, 1990.
80.
BellCJ, ElliottEJ, WallaceJL, RedmondDM, PayneJ, LiZ, O'LoughlinEV. Do eicosanoids cause colonic dysfunction in experimental E. coli 0157:H7 (EHEC) infection? Gut46:806–812, 2000.
81.
StensonWF, LauritsenK, LaursenLS, Rask-MadsenJ, JacobsenO, NaesdalJ, CortD, GoebellH, PeskarB, HanauerS, SwansonL, DubeL, RubinP.A clinical trial of Zileuton, a specific inhibitor of 5-lipoxygenase, in ulcerative colitis. Gastroenterology100:A253, 1991.
82.
BukhaveK, LaursenLS, LauritsenK, Rask-MasdenJ, NaesdalJ, JacobsenO, GoebellH, PeskarB, CortD, StensonW, HanauerS.5-Lipoxygenase inhibition in double-blind trial with zileuton: how much is sufficient in active ulcerative colitis?Gastroenterology100:A200, 1991.
83.
KanwarS, JohnstonB, KubesP.Leukotriene C4/D4 induces P-selectin and sialyl Lewisx-dependent alterations in leukocyte kinetics in vivo. Circ Res77:879–887, 1995.
84.
WallaceJL, McKnightGW, KeenanCM, BylesNIA, MacNaughtonWK. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology98:1178–1186, 1990.
85.
RiouxKP, WallaceJL. Mast cell activation augments gastric mucosal injury through a leukotriene-dependent mechanism. Am J Physiol266:G863–G869, 1994.
PerdueMH, RamageJK, BurgetD, MarshallJ, MassonS.Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Dig Dis Sci34:724–731, 1989.
88.
HiggsGA, MoncadaS, SalmonJA, SeagerK.The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol89:1162–1188, 1985.
89.
GoldmanG, WelbournR, ValeriCR, SheproD, HechtmanHB. Thromboxane A2 induces leukotriene B4 synthesis that in turn mediates neutrophil diapedesis via CD 18 activation. Microvas Res41:367–375, 1991.
90.
WhittleBJR, KauffmanGL, MoncadaS.Vasoconstriction with thromboxane A2 induces ulceration of the gastric mucosa. Nature292:472–474, 1981.
91.
WhittleBJR, Oren-WolmanRN, GuthPH. Gastric vasoconstrictor actions of leukotriene C4, PGF2α, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol248:G580–G586, 1985.
92.
KonturekSJ, BrzozowskiT, PiastuckiI, RadeckiT, Dembinska-KiecA.Role of prostaglandin and thromboxane biosynthesis in gastric necrosis produced by taurocholate and ethanol. Dig Dis Sci28:154–160, 1983.
93.
WaltRP, KempRT, FilipowiczB, DaviesJG, BhaskarNK, HawkeyCJ. Gastric mucosal protection with selective inhibition of thromboxane synthesis. Gut28:541–544, 1987.
94.
TakahashiS, ShigetaJ, IshikawaM, KobayashiN, OkabeS.Role of thromboxane A2 in healing of gastric ulcers in rats. Jpn J Pharmacol79:101–107, 1999.
95.
HawkeyCJ. Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer. Gut27:1484–1492, 1986.
96.
Boughton-SmithNK, HutchesonI, WhittleBJR. Relationship between PAF-acether and thromboxane A2 biosynthesis in endotoxin-induced intestinal damage in the rat. Prostaglandins38:319–333, 1989.
VilasecaJ, SalasA, GuarnerF, RodriguezR, MalageladaJ-R. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology98:269–277, 1990.
100.
TaniguchiT, TsukadaH, NakamuraH, KodamaM, FukudaK, TominagaM, SeinoY.Effects of a thromboxane A2 receptor antagonist in an animal model of inflammatory bowel disease. Digestion58:476–478, 1997.
101.
Van OutryveM, HubleF, Van EeghemP, De VosM.Comparison of ridogrel versus prednisolone, both administered rectally, for the treatment of active ulcerative colitis. Gastroenterology110:A1035, 1996.
102.
CasellasF, PapoM, GuarnerF, AntolinM, SeguraRM, ArmengolJR, MalageladaJR. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis. Eur J Gastroenterol Hepatol7:221–226, 1995.
103.
SkandalisN, RotenbergA, MeuwissenS, de GrootGH, OuwendijkRJT, TanTG. Ridogrel for the treatment of mild to moderate ulcerative colitis. Gastroenterology110:A1016, 1996.
104.
SnyderF.Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol259:C697–C708, 1990.
105.
RosamAC, WallaceJL, WhittleBJR. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature319:54–56, 1986.
106.
Gonzalez-CrussiF, HsuehW.Experimental model of ischemic bowel necrosis. Am J Pathol112:127–135, 1983.
107.
WallaceJL, WhittleBJR. Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins31:989–998, 1986.
108.
WallaceJL, SteelG, WhittleBJR, LagenteV, VargaftigB.Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Gastroenterology93:765–773, 1987.
109.
WallaceJL, HogaboamCM, McKnightGW. Platelet-activating factor mediates gastric damage induced by hemorrhagic shock. Am J Physiol259:G140–G146, 1990.
110.
KubesP, IbbotsonG, RussellJ, WallaceJL, GrangerDN. Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol259:G300–G305, 1990.
111.
KubesP, SuzukiM, GrangerDN. Platelet-activating factor-induced microvascular dysfunction: role of adherent leukocytes. Am J Physiol258:G158–G163, 1990.
112.
SunXM, QuXW, HuangW, GrangerDN, BreeM, HsuehW.Role of leukocyte β2-integrin in PAF-induced shock and intestinal injury. Am J Physiol270:G184–G190, 1996.
113.
ZimmermanGA, McIntyreTM, MehraM, PrescottSM. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol110:529–540, 1990.
114.
HsuehW, Gonzalez-CrussiF, ArroyaveJL. Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia. FASEB J1:403–405, 1987.
115.
HsuehW, Gonzalez-CrussiF, ArroyaveJL. Release of leukotriene C4 by isolated, perfused rat small intestine in response to platelet-activating factor. J Clin Invest78:108–114, 1986.
116.
HogaboamCM, BefusAD, WallaceJL. Intestinal platelet-activating factor synthesis during Nippostrongylus brasiliensis infection in the rat. J Lipid Mediators4:211–224, 1991.
117.
HogaboamCM, WallaceJL. Intestinal PAF synthesis: the role of the mast cell. J Lipid Mediators10:103–105, 1994.
118.
HanglowAC, BienenstockJ, PerdueMH. Effects of platelet-activating factor on ion transport in isolated rat jejunum. Am J Physiol257:G845–G850, 1989.
119.
EliakimR, KarmeliF, RazinE, RachmilewitzD.Role of platelet-activating factor in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazin e and prednisolone. Gastroenterology95:1167–1172, 1988.
120.
WallaceJL. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis. Can J Physiol Pharmacol66:422–425, 1988.
121.
WallaceJL, BraquetP, IbbotsonGC, MacNaughtonWK, CirinoG.Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease. J Lipid Med1:13–23, 1989.
122.
WillPC, ThomasTK, IversonL, BuckmanD, WeisW, WilsonC, SrivastavaA.Platelet activating factor as a proinflammatory mediator in acetic acid-induced colitis in the rat. Agents Actions34:181–184, 1991.
123.
DenizotY, ChaussadeS, NathanN, ColombelJF, BossantM-J, CheroukiN, BenvenisteJ, CouturierD.PAF-acether and acetylhydrolase in stool of patients with Crohn's disease. Dig Dis Sci37:432–437, 1992.
124.
FerrarisL, KarmeliF, EliakimR, KleinJ, FiocchiC, RachmilewitzD.Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut34:665–668, 1993.
125.
ReinshagenM, PatelA, SottiliM, FrenchS, SterniniC, EysseleinVE. Action of sensory neurons in an experimental rat colitis model of injury and repair. Am J Physiol270:G79–G86, 1996.
126.
SteadRH, DixonMF, BramwellNH, RiddellRH, BienenstockJ.Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology97:575–585, 1989.
127.
ShanahanF, DenburgJA, FoxJ, BienenstockJ, BefusD.Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol135:1331–1337, 1985.
128.
WallaceJL, McKnightGW, BefusAD. Capsaicin-induced hyperemia in the stomach: possible contribution of mast cells. Am J Physiol263:G209–G214, 1992.
129.
SungC-P, ArlethAJ, FeuersteinGZ. Neuropeptide Y up-regulates the adhesiveness of human endothelial cells for leukocytes. Circ Res68:314–318, 1991.
130.
RaithelM, SchneiderHT, HahnEG. Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease. Scand J Gastroenterol34:496–503, 1999.
131.
MatisWL, LavkerRM, MurphyGF. Substance P induces the expression of an endothelial-leukocyte adhesion molecule by microvascular endothelium. J Invest Dermatol94:492–495, 1990.
132.
WershilBK, WangZ-S, GalliSJ. Gastric inflammation in the mouse: evidence of mast cell-dependent neutrophil infiltration during IgE-dependent or substance P-induced inflammation. Gastroenterology102:A712, 1992.
133.
DinarelloCA. Cytokines: interleukin-1 and tumour necrosis factor (cachectin). In: GallinJI, GoldsteinIM, SnydermanR, Eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, ppl95–208, 1988.
134.
DinarelloCA. The interleukin-1 family: 10 years of discovery. FASEB J8:1314–1325, 1994.
135.
BeckPL, WallaceJL. Cytokines in inflammatory bowel disease. Mediators Inflamm6:95–103, 1997.
136.
RobertA, OlafssonAS, LancasterC, ZhangW.Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci48:123–134, 1990.
137.
WallaceJL, KeenanCM, CucalaM, MugridgeKG, ParenteL.Mechanisms underlying the protective effects of interleukin-1 in experimental NSAID gastropathy. Gastroenterology102:1176–1185, 1992.
138.
ShibasakiT, YamauchiN, HottaM, ImakiT, OdaT, LingN, DemuraH.Interleukin-1 inhibits stress-induced gastric erosion in rats. Life Sci48:2267–2273, 1991.
139.
WallaceJL, KeenanCM, MugridgeKG, ParenteL.Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1β. Eur J Pharmacol186:279–284, 1990.
140.
UeharaA, OkumuraT, SekiyaC, OkamuraK, TakasugiY, NamikiM.Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. Biochem Biophys Res Commun162:1578–1584, 1989.
141.
WallaceJL, CucalaM, MugridgeK, ParenteL.Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol261:G559–G564, 1991.
142.
SaperasES, YangH, RivierC, TacheY.Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Gastroenterology99:1599–1606, 1990.
143.
WuKK, SandujaR, TsaiAL, FerhanogluB, Loose-MitchellDS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A88:2384–2387, 1991.
144.
PalmerRM, HickeryMS, CharlesIG, MoncadaS, BaylissMT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun193:398–405, 1993.
145.
AppleyardCB, McCaffertyDM, TigleyAW, SwainMG, WallaceJL. Tumour necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol270:G42–G48, 1996.
146.
MurchSH, LamkinVA, SavageMO, Walker-SmithJA, MacDonaldTT. Serum concentrations of tumour necrosis factor-α in childhood chronic inflammatory bowel disease. Gut32:913–917, 1991.
147.
BraeggerCP, NichollsS, MurchSH, StephensS, MacDonaldTT. Tumour necrosis factor-α in stool as a marker of intestinal inflammation. Lancet339:89–91, 1992.
148.
MurchSH, BraeggerCP, Walker-SmithJA, MacDonaldTT. Location of tumour necrosis factor-α by immunohistochemistry in chronic inflammatory bowel disease. Gut34:1705–1709, 1993.
149.
Van DullemenHM, Van DeventerSJH, HommesDW, BijlHA, JansenJ, TytgatGNJ, WoodyJ.Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology109:129–135, 1995.
150.
SchreiberS, CampieriM, ColombelJF, van DeventerSJ, FeaganB, FedorakR, ForbesA, GassullM, GendreJP, van HogezandRA, LofbergR, ModiglianiR, PalloneF, PetritschW, PranteraC, RamptonD, SeiboldF, VatnM, ZeitzM, RutgeertsP.Use of anti-tumour necrosis factor agents in inflammatory bowel disease: European guidelines for 2001–2003. Int J Colorectal Dis16:1–11, 2001.
151.
StordeurP, GoldmanM.Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. Int Rev Immunol16:501–522, 1998.
152.
MooreKW, O'GarraA, de Waal MalefytR, VieiraP, MosmannTR. Interleukin-10. Annu Rev Immunol11:165–190, 1993.
153.
CasatellMA, MedaL, GasperiniS, BonoraS.Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med179:1695–1699, 1994.
AkagiS, HiyamaE, ImamuraY, TakesueY, MatsuuraY, YokoyamaT.Interleukin-10 expression in intestine of Crohn's disease. Int J Mol Med5:389–395, 2000.
156.
NicolausS, BauditzJ, GionchettiP, WittC, LochsH, SchreiberS.Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut42:470–476, 1998.
SteidlerL, HansW, SchotteL, NeirynckS, ObermeierF, FalkW, FiersW, RemautE.Treatment of murine colitis by Lactococcus lactis-secreting interleukin-10. Science289:1352–1355, 2000.
159.
BarbaraG, XingZ, HogaboamCM, GauldieJ, CollinsSM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut46:344–349, 2000.
160.
DeryO, CorveraCU, SteinhoffM, BunnettNW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol274:C1429–C1452, 1998.
161.
HollenbergMD. Protease-activated receptors: PAR4 and counting: how long is the course?Trends Pharmacol Sci20:271–273, 1999.
162.
SaifeddineM, Al-AniB, ChengCH, WangL, HollenbergMD. Rat proteinase-activated receptor-2 (PAR2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol118:521–530, 1996.
163.
VergnolleN, HollenbergMD, SharkeyKA, WallaceJL. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol127:1083–1090, 1999.
164.
VergnolleN, WallaceJL, BunnettNW, HollenbergMD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci22:146–152, 2001.
165.
SteinhoffM, VergnolleN, YoungSH, TognettoM, AmadesiS, EnnesHS, TrevisaniM, HollenbergMD, WallaceJL, CaugheyGH, MitchellSE, WilliamsLM, GeppettiP, MayerEA, BunnettNW. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med6:151–158, 2000.
166.
CorveraCU, DeryO, McConalogueK, GampP, ThomaM, Al-AniB, CaugheyGH, HollenbergMD, BunnettNW. Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and −2. J Physiol (Lond)517:741–756, 1999.
CocksTM, FongB, ChowJM, AndersonGP, FraumanAG, GoldieRG, HenryPJ, CarrMJ, HamiltonJR, MoffattJD. A protective role for protease-activated receptors in the airways. Nature398:156–160, 1999.
169.
KoshikawaN, NagashimaY, MiyagiY, MizushimaH, YanomaS, YasumitsuH, MiyazakiK.Expression of trypsin in vascular endothelial cells. FEBS Lett409:442–448, 1997.
170.
MolinoM, BarnathanES, NumerofR, ClarkJ, DreyerM, CumashiA, HoxieJA, SchechterN, WoolkalisM, BrassLF. Interactions of mast cell tryptase with thrombin receptors and PAR2. J Biol Chem272:4043–4049, 1997.
171.
SteadRH, TomiokaM, QuinonezG, SimonGT, FeltenSY, BienenstockJ.Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc Nat Acad Sci U S A84:2975–2979, 1987.
172.
TheoharidesTC. Mast cells: the immune gate to the brain. Life Sci46:607–617, 1990.
